Overcoming resistance to MAPK pathway inhibitors

J Natl Cancer Inst. 2013 Jan 2;105(1):9-10. doi: 10.1093/jnci/djs507. Epub 2012 Dec 17.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Benzamides / pharmacology*
  • Benzimidazoles / pharmacology*
  • Humans
  • Melanoma / drug therapy*
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • Molecular Targeted Therapy / methods*
  • Ubiquitin-Protein Ligases / metabolism*

Substances

  • 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide
  • AZD 6244
  • Antineoplastic Agents
  • Benzamides
  • Benzimidazoles
  • SMURF2 protein, human
  • Ubiquitin-Protein Ligases
  • Mitogen-Activated Protein Kinases